Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Drug combo effective against uterine fibroids in trial
By (0)
A new combo pill can substantially reduce bleeding caused by uterine fibroids possibly offering some women yet another alternative to surgery, a new trial finds.
The once-daily medication, which combines a drug called relugolix with estrogen and progestin, is not yet approved in the United States.
Advertisement
But it is under review by the U.S. Food and Drug Administration, according to drugmaker Myovant Sciences, which funded the study.
If approved, the drug would join a similar medication called Oriahnn that got the green light from the FDA last year for reducing heavy bleeding from fibroids.
iStock
There s good news for women of reproductive age who are coping with the debilitating side effects of uterine fibroids, the benign growths on the uterus that can cause massive bleeding, pain, anemia, painful sex, miscarriage, or infertility.
A study published February 18, 2021, in the
New England Journal of Medicine has found that a daily combination oral therapy of 40 milligrams (mg) of the drug relugolix (Relugolix-CT) with small doses of synthetic estrogen (1 mg estradiol) and synthetic progesterone (.5 mg norethindrone acetate) led to dramatic improvement in symptoms and, to a lesser degree, shrinkage of the uterine fibroids themselves. The therapy, which is given as one pill, is currently under review by the U.S. Food and Drug Administration (FDA), with approval anticipated for this summer (mid-2021).
New Drug Combo Effective Against Uterine Fibroids newsmax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsmax.com Daily Mail and Mail on Sunday newspapers.